Dr. Goy on Takeaways in Mantle Cell Lymphoma for the Future

Andre Goy, MD, MS
Published: Friday, Feb 03, 2017



Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the takeaways for community oncologists in the field of mantle cell lymphoma (MCL).

It is important for researchers in the field to understand the significance of minimal residual disease and achieving a complete response (CR), Goy explains. There are tools available to make this happen, he adds. Also, researchers can limit therapy in patients who achieve a CR, and this will likely have a positive impact on cost control.

Combination regimens will also be a part of the future treatment landscape, says Goy. A potential option, he adds, includes chemotherapy as a maintenance therapy.
SELECTED
LANGUAGE


Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the takeaways for community oncologists in the field of mantle cell lymphoma (MCL).

It is important for researchers in the field to understand the significance of minimal residual disease and achieving a complete response (CR), Goy explains. There are tools available to make this happen, he adds. Also, researchers can limit therapy in patients who achieve a CR, and this will likely have a positive impact on cost control.

Combination regimens will also be a part of the future treatment landscape, says Goy. A potential option, he adds, includes chemotherapy as a maintenance therapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x